Treatment Duration for Major Depressive Disorder
For a first episode of major depressive disorder, continue antidepressant treatment for 4 to 9 months after achieving remission; for patients with two or more previous episodes, treatment should continue for years to lifelong. 1
Treatment Duration Based on Episode History
First Episode of MDD
The American College of Physicians provides a strong recommendation (moderate-quality evidence) that clinicians continue antidepressant therapy for 4 to 9 months after a satisfactory response in patients experiencing their first episode of major depressive disorder 1. This continuation phase is critical because it prevents relapse—defined as the return of symptoms during the period when the initial episode is still considered active.
More recent evidence from 2015 supports a minimum duration of 4 to 12 months after the first episode 2. The rationale is straightforward: after a first episode, approximately 50% of patients will experience a recurrence if treatment is discontinued prematurely 2.
Recurrent Depression (Two or More Episodes)
Patients with two or more depressive episodes require substantially longer treatment—potentially years to lifelong maintenance therapy 1. The evidence supporting this is compelling:
- After two episodes, the probability of recurrence increases to 70%
- After three episodes, recurrence risk reaches 90% 2
The 2015 American Family Physician guidelines note that patients with recurrent depression (defined as three or more episodes) who were treated to remission and then continued on maintenance therapy had significantly lower recurrence rates compared to those switched to placebo 2.
Critical Timing Considerations
Minimum Treatment Duration to Reduce Relapse Risk
Recent research from 2024 demonstrates that treatment duration under 3 months is associated with a relatively higher risk of relapse after discontinuation 3. The meta-analysis shows a non-linear relationship where:
- Treatment less than 3 months: substantially elevated relapse risk
- Treatment of 3-6 months: moderate benefit
- Treatment beyond 6 months: no further significant reduction in relapse risk for first episodes 3
However, a 2021 Danish population-based cohort study of 89,442 adults found that 10-12 months of treatment appears optimal if there is concern about relapse after discontinuation 4. Patients who discontinued antidepressants before 10 months had higher risks of restarting treatment:
- <4 months: 21% increased risk (HR 1.21)
- 4-6 months: 11% increased risk (HR 1.11)
- 7-9 months: 9% increased risk (HR 1.09)
The Acute Phase Assessment
Before counting the continuation phase, assess treatment response at 6 to 8 weeks after initiation 1. If there is inadequate response by this point, modify treatment rather than continuing an ineffective regimen. The response rate to initial drug therapy may be as low as 50% 1.
Monitoring Requirements
Begin monitoring within 1 to 2 weeks of starting antidepressant therapy 1. This early monitoring is FDA-mandated due to increased risk of suicidal thoughts and behaviors, particularly during the first 1 to 2 months of treatment. Monitor for:
- Suicidal ideation or behavior
- Agitation or irritability
- Unusual behavioral changes indicating worsening depression
Common Pitfalls to Avoid
Do not discontinue antidepressants at the end of the acute phase (when symptoms first resolve). This is the most common error—the 4-9 month continuation period begins after achieving remission, not after starting treatment 1, 5.
Do not assume all patients need the same duration. Episode history is the primary determinant:
- First episode: 4-9 months minimum after remission
- Two episodes: Consider extended maintenance (years)
- Three or more episodes: Strong consideration for indefinite maintenance therapy 1, 2
The evidence consistently shows that antidepressant medication does not prevent relapse if discontinued at the end of the acute phase, and systematic reviews confirm that continued treatment after remission protects against both relapse and recurrence 2.